NLRP3 and migraine disorder: Although the treatment approaches for migraine are not yet well established, IL-1 receptor antagonists suppress migraine attacks in patients with the cryopyrin-associated periodic syndrome, where mutations in the inflammasome component NLRP3 result in over secretion of IL-1β [120,121].